Interv Akut Kardiol. 2010;9(3):158-159

CHAMPION-PLATFORM trial

Stanislav Šimek
II. interní klinika kardiologie a angiologie, 1. LF UK a VFN, Praha

The international randomized CHAMPION-PLATFORM trial investigated the use of cangrelor, a novel intravenous inhibitor of the platelet

ADP receptor, in patients requiring PCI. Although the occurrence of the primary endpoint (a composite of death, myocardial infarction, or

revascularization) was not significantly affected by administering cangrelor, the 30-day mortality and the rate of stent thrombosis were

significantly lower in the actively treated group. If the beneficial effect on patient prognosis is confirmed during one-year follow-up of

patients of this trial and in subsequent research, cangrelor may become standard treatment during coronary interventions.

Keywords: cangrelor, ad-hoc PCI, antiplatelet therapy

Published: June 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šimek S. CHAMPION-PLATFORM trial. Interv Akut Kardiol. 2010;9(3):158-159.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Storey RF, Sanderson HM, White AE, et al. The central role of the P (2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000; 110: 925-934. Go to original source... Go to PubMed...
    2. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous Platelet Blockade with Cangrelor during PCI. N Engl J Med 2009; 361: 2330-2341. Go to original source... Go to PubMed...
    3. Harrington RA, Stone GW, McNulty S, et al. Platelet Inhibition with Cangrelor in Patients Undergoing PCI. N Engl J Med 2009; 361: 2318-2329. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.